Loading...
Nippon Chemiphar Co., Ltd.
4539.T•JPX
Healthcare
Drug Manufacturers - Specialty & Generic
¥1541.00
¥2.00(0.13%)
Nippon Chemiphar Co., Ltd. (4539.T) Financial Performance & Income Statement Overview
Review Nippon Chemiphar Co., Ltd.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
5.93%
↑ 5.93%
Operating Income Growth
222.87%
↑ 222.87%
Net Income Growth
263.33%
↑ 263.33%
Operating Cash Flow Growth
-189.53%
↓ 189.53%
Operating Margin
1.86%
↑ 1.86%
Gross Margin
26.85%
↑ 26.85%
Net Profit Margin
0.90%
↑ 0.90%
ROE
1.58%
↑ 1.58%
ROIC
1.61%
↑ 1.61%
Nippon Chemiphar Co., Ltd. (4539.T) Income Statement & Financial Overview
Review Nippon Chemiphar Co., Ltd.'s (4539.T) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $8.26B | $8.68B | $7.63B | $8.00B |
| Cost of Revenue | $6.005B | $6.31B | $5.61B | $5.90B |
| Gross Profit | $2.26B | $2.37B | $2.02B | $2.09B |
| Gross Profit Ratio | $0.27 | $0.27 | $0.27 | $0.26 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $2.007B | $2.09B | $1.95B | $2.09B |
| Operating Expenses | $2.007B | $2.09B | $1.95B | $2.09B |
| Total Costs & Expenses | $8.01B | $8.40B | $7.56B | $7.99B |
| Interest Income | $1.00M | $2.00M | $2.00M | $0.00 |
| Interest Expense | $54.00M | $54.00M | $47.00M | $43.00M |
| Depreciation & Amortization | $362.00M | $364.75M | $320.00M | $346.00M |
| EBITDA | $574.00M | $643.75M | $118.00M | $548.00M |
| EBITDA Ratio | $0.07 | $0.07 | $0.02 | $0.07 |
| Operating Income | $251.00M | $279.00M | $74.00M | $3.00M |
| Operating Income Ratio | $0.03 | $0.03 | $0.010 | $0.00 |
| Other Income/Expenses (Net) | -$91.00M | -$124.00M | -$297.00M | $157.00M |
| Income Before Tax | $160.00M | $155.00M | -$223.00M | $160.00M |
| Income Before Tax Ratio | $0.02 | $0.02 | -$0.03 | $0.02 |
| Income Tax Expense | -$98.00M | $74.00M | -$51.00M | $34.00M |
| Net Income | $259.00M | $79.00M | -$170.00M | $126.00M |
| Net Income Ratio | $0.03 | $0.009 | -$0.02 | $0.02 |
| EPS | $71.79 | $21.90 | -$47.11 | $34.92 |
| Diluted EPS | $71.79 | $21.90 | -$47.11 | $34.92 |
| Weighted Avg Shares Outstanding | $3.61M | $3.61M | $3.61M | $3.61M |
| Weighted Avg Shares Outstanding (Diluted) | $3.61M | $3.61M | $3.61M | $3.61M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan